Henderson Group Plc Janus Purchases 28,326 Shares of ARCA biopharma, Inc. (NASDAQ:ABIO) Stock

ARCA biopharma, Inc. (NASDAQ:ABIO) major shareholder Henderson Group Plc Janus purchased 28,326 shares of the stock in a transaction on Friday, July 5th. The stock was acquired at an average cost of $3.43 per share, for a total transaction of $97,158.18. Following the completion of the acquisition, the insider now owns 1,676,903 shares of the company’s stock, valued at approximately $5,751,777.29. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Henderson Group Plc Janus also recently made the following trade(s):

• On Wednesday, July 10th, Henderson Group Plc Janus acquired 55,463 shares of ARCA biopharma stock. The stock was purchased at an average price of $3.46 per share, with a total value of $191,901.98.
• On Monday, July 8th, Henderson Group Plc Janus acquired 47,492 shares of ARCA biopharma stock. The stock was purchased at an average price of $3.46 per share, with a total value of $164,322.32.
• On Wednesday, July 3rd, Henderson Group Plc Janus purchased 166,042 shares of ARCA biopharma stock. The shares were bought at an average price of $3.55 per share, with a total value of $589,449.10.

ARCA biopharma Stock Up 0.9 %

Shares of ARCA biopharma stock traded up $0.03 during mid-day trading on Friday, hitting $3.35. The stock had a trading volume of 14,055 shares, compared to its average volume of 713,609. The firm has a 50-day moving average of $3.43 and a two-hundred day moving average of $2.54. ARCA biopharma, Inc. has a 12-month low of $1.56 and a 12-month high of $4.49. The firm has a market cap of $48.61 million, a P/E ratio of -7.98 and a beta of 0.90.

ARCA biopharma (NASDAQ:ABIO) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter.

Institutional Investors Weigh In On ARCA biopharma

A hedge fund recently bought a new stake in ARCA biopharma stock. abrdn plc acquired a new stake in ARCA biopharma, Inc. (NASDAQ:ABIO) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 32,461 shares of the biopharmaceutical company’s stock, valued at approximately $55,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of ARCA biopharma in a research note on Wednesday, May 22nd. They set a “sell” rating for the company.

About ARCA biopharma

ARCA biopharma, Inc, a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure.